A new meta-analysis of fourteen studies finds that patients with beta-thalassemia major show significantly elevated seroprevalence and more than double the risk of Toxoplasma gondii infection compared ...
Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset
Japan’s Ono Pharmaceutical is paying $80 million upfront for the regional rights to a trio of Biohaven’s IgG degraders led by ...
Asianet Newsable on MSN
IMVT, ROIV stocks slide as Argenx Sjögren’s trial failure hits drug class
Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s ...
To you who were told you are 'H. pylori antibody positive' during a health checkup—what a medical laboratory technician wants ...
A peer-reviewed study reports ACES Diagnostics’ LymeSeek test achieved 90% sensitivity for early Lyme disease detection.
Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, ...
Deleting the Ssu72 phosphatase specifically in B cells sharply reduces IgE and IgG1 production and lung inflammation in a ...
A new peer-reviewed study published in the Journal of Clinical Microbiology demonstrates the potential of LymeSeek™, a single-tier Lyme disease diagnostic test developed by ACES Diagnostics and its ...
AM CETAmsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today ...
FairJourney Bio’s Maria Gonzalez Pajuelo reflects on her early work with nanobodies, the potential of single-domain ...
Today, CiteAb released its annual Top 100 Reports, covering the most-cited Research Antibodies, Proteins, Kits & Assays, Cell Lines, Bioactive Small Molecules, and Instruments in life science research ...
A nursing calf is not always a protected calf. Research shows up to 34.5% suffer from failed passive transfer — and targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results